Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 14/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 14/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.62 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | SCN4A | P35499 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL975901 | 0.84 | ADORA2A (0.67) | ADORA2AADORA1ADORA2BCSNK1A1CLK4 | |
| SCHEMBL9848552 | 0.82 | CSNK1A1 (0.53) | ADORA2AADORA1ADORA2BCSNK1A1CLK4 | |
| SCHEMBL10843457 | 0.82 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BCSNK1A1CLK4 | |
| SCHEMBL7349151 | 0.80 | CSNK1A1 (0.66) | ADORA2AADORA1ADORA2BCSNK1A1CLK4 | |
| SCHEMBL2322183 | 0.77 | ADORA2A (1.00) | ADORA2AADORA1ADORA2B | |
| SCHEMBL6492186 | 0.76 | CSNK1A1 (0.55) | ADORA2AADORA1ADORA2BCSNK1A1CLK4 | |
| SCHEMBL2321662 | 0.75 | ADORA2A (0.75) | ADORA2AADORA1ADORA2B | |
| SCHEMBL978226 | 0.74 | SCN9A (0.61) | ADORA2AADORA1ADORA2BCSNK1A1CLK4 | |
| SCHEMBL30413401 | 0.74 | SCN9A (0.61) | ADORA2AADORA1ADORA2BCSNK1A1CLK4 | |
| SCHEMBL17838938 | 0.74 | CSNK1A1 (0.57) | ADORA2AADORA1ADORA2BCSNK1A1CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2043656-B1 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | UNIV GREENWICH (GB) | 2014-02-12 | — | — | EP | disclosed |
| US-20130005732-A1 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | UNIVERSITY OF GREENWICH (GB) | 2013-01-03 | — | — | US | disclosed |
| US-8268823-B2 | Medical use of triazine derivatives | UNIVERSITY OF GREENWICH (GB) | 2012-09-18 | — | — | US | disclosed |
| US-20090291954-A1 | Medical Use of Triazine Derivatives | UNIVERSITY OF GREENWICH (GB) | 2009-11-26 | — | — | US | disclosed |
| EP-2043656-A2 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | University of Greenwich (GB) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008007149-A2 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | UNIVERSITY OF GREENWICH (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291954-A1 | Medical Use of Triazine Derivatives | KCNH1, KCNJ1, KCNN1 | ADORA2A 302/4885ADORA1 337/4885ADORA2B 235/4885 |
| US-20130005732-A1 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | KCNJ1, KCNH1, KCNJ11 | ADORA2A 280/4885ADORA1 248/4885ADORA2B 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.